Akeso IO2.0 + ADC2.0 Strategy Makes Another Advancement: First Patient Dosed in Phase Ib/II Study of HER3 ADC (AK138D1) Combined with Ivonescimab in Lung Cancer

Phase 2AK138D1IvonescimabPositive

AI Analysis

Summary

Akeso announced first patient dosing in Phase Ib/II study (AK138D1-201) of its HER3 ADC candidate AK138D1 combined with ivonescimab for lung cancer treatment.

Clinical Trial Data

Phase

Ib/II

Outcome Details

First patient dosed in Phase Ib/II study

Importance:5/10

Sentiment:

0.60

HER3 ADCCombination therapyLung cancerEarly-stage trial

Related Companies

$GBIO $TRAX

Read the original article

Published by PR Newswire Clinical Trials on July 28, 2026 2:35 AM

Read Original